Varsity Healthcare Partners Completes Sale of Probo Medical

Varsity Healthcare Partners (“VHP”), a leading healthcare services private equity investment firm, announced today the close of its sale of Probo Medical, LLC (“Probo” or “the Company”) to Avista Capital Partners (“Avista”). Terms of the transaction were not disclosed.

VHP initially invested in Probo in September 2018, at which point Probo was focused exclusively on the U.S. ultrasound repair and resale market. Since that time, the VHP and Probo partnership has worked collaboratively to both grow and diversify the Company’s service lines, leveraging an organic and targeted acquisition strategy to expand Probo’s recurring service capabilities globally.

Today, Probo offers a vertically integrated set of medical imaging products and services to customers worldwide, including equipment sales, part sales, equipment rentals, depot repair service, equipment installation and de-installation, and contractual field-based repair service.

The Company also now provides its full suite of services across a spectrum of imaging modalities, including Ultrasound, PET, X-Ray, C-Arms, CT Scanners, MRI, and Mammography machines.

Probo’s footprint includes fourteen facilities across the United States, the United Kingdom, Germany, France, and Canada, breaking into international markets as demand continues to grow for refurbished imaging equipment and service solutions that extend machinery lifespan.

Cain Brothers, a division of KeyBanc Capital Markets, acted as lead financial advisor, Houlihan Lokey acted as co-financial advisor, and Morgan Lewis acted as legal advisor to Varsity Healthcare Partners. Ropes & Gray acted as legal advisor to Avista Capital Partners.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”